Durbin, Anna Palmer
- Johns Hopkins University · Public Health (NIH department code)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #1,733
- Top 10% Funded
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2023 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2023 award categories
- Public Health
NIH Funding · FY2023
Linked Award Amount
$3.1M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#1,733
By linked amount among FY2023 PIs
Earliest Year Loaded
2023
ScienceDex PI coverage
Award data coverage
ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.
Single fiscal year on record (FY2023): $3.1M in linked award amounts across 1 award record · Award-linked rank #1733.
FY2023 award records by amount
NIH award records listing Durbin, Anna Palmer as a PI. Multi-PI records show the full award amount for context.
- 75N93019D00031-0-759302300004-1N01Contact PIA STUDY TO ASSESS EFFICACY, SAFTETY AND PHARMACOKINETICS OF EYU688 IN HEALTHY PARTICIPANTS CHALLENGED WITH DENGUE SEROTYPE 2Johns Hopkins University · Public Health (NIH department code)$3.1Maward amount
Award organization
Organizations that administered FY2023 awards listing Durbin, Anna Palmer as a PI.
FY2023 award administered by Johns Hopkins University (MD).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2023First NIH AwardJohns Hopkins University
- 2023$500K Cumulative Funding
- 2023$1M Cumulative Funding
- 2023$2M Cumulative Funding
- 2023Entered Top 50% NationallyRanked #1733
- 2023Entered Top 25% NationallyRanked #1733
- 2023Entered Top 10% NationallyRanked #1733